WEBULL
News
TERN
37.77
+6.88%
2.43
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)
TipRanks · 4d ago
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Simply Wall St · 5d ago
Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan
Reuters · 6d ago
Terns Pharmaceuticals gewährt neuen Mitarbeitern Aktienoptionen als Vergütungsanreiz
Reuters · 6d ago
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders
Simply Wall St · 6d ago
Weekly Report: what happened at TERN last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at TERN last week (0119-0123)?
Weekly Report · 01/26 09:43
Mizuho Securities Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
TipRanks · 01/23 11:17
Terns Pharmaceuticals Amends Its Current Exclusive Option And License Agreement With Hansoh Healthtech
Benzinga · 01/22 21:45
Terns Pharmaceuticals Expands Global Rights to TERN-701
TipRanks · 01/22 21:33
TERNS PHARMACEUTICALS: OBLIGATED TO PAY HANSOH ONE-TIME UPFRONT LICENSE FEE $1.0 MLN & TIERED ROYALTIES 0.75% TO 1.25% ON ANNUAL NET SALES
Reuters · 01/22 21:11
TERNS PHARMACEUTICALS INC - AMENDS LICENSE AGREEMENT WITH HANSOH HEALTHTECH - SEC FILING
Reuters · 01/22 21:11
Terns Pharmaceuticals Grants Hansoh Exclusive License for TERN-701 Patents Outside Greater China
Reuters · 01/22 21:08
Weekly Report: what happened at TERN last week (0112-0116)?
Weekly Report · 01/19 09:46
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise
Simply Wall St · 01/17 16:24
How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data
Simply Wall St · 01/15 20:42
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
TipRanks · 01/14 18:05
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
TipRanks · 01/14 17:50
TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals
TipRanks · 01/13 09:55
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.